华森制药：子公司获得《药物临床试验批准通知书》

Group 1 - The company Huason Pharmaceutical announced that its subsidiary, Chongqing Huason Inno Biotech Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of HSN002066C1 tablets in two specifications [1] - This approval marks a significant step in the company's research and development efforts in the pharmaceutical sector [1] - The clinical trial approval is expected to enhance the company's product pipeline and potentially lead to new market opportunities [1]